Literature DB >> 21839398

Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.

Colin Green1, James Shearer, Craig W Ritchie, John P Zajicek.   

Abstract

OBJECTIVE: To consider the methods available to model Alzheimer's disease (AD) progression over time to inform on the structure and development of model-based evaluations, and the future direction of modelling methods in AD.
METHODS: A systematic search of the health care literature was undertaken to identify methods to model disease progression in AD. Modelling methods are presented in a descriptive review.
RESULTS: The literature search identified 42 studies presenting methods or applications of methods to model AD progression over time. The review identified 10 general modelling frameworks available to empirically model the progression of AD as part of a model-based evaluation. Seven of these general models are statistical models predicting progression of AD using a measure of cognitive function. The main concerns with models are on model structure, around the limited characterization of disease progression, and on the use of a limited number of health states to capture events related to disease progression over time. None of the available models have been able to present a comprehensive model of the natural history of AD.
CONCLUSIONS: Although helpful, there are serious limitations in the methods available to model progression of AD over time. Advances are needed to better model the progression of AD and the effects of the disease on peoples' lives. Recent evidence supports the need for a multivariable approach to the modelling of AD progression, and indicates that a latent variable analytic approach to characterising AD progression is a promising avenue for advances in the statistical development of modelling methods.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21839398     DOI: 10.1016/j.jval.2010.12.008

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  27 in total

1.  Evaluating disease-modifying agents: a simulation framework for Alzheimer's disease.

Authors:  Shien Guo; Denis Getsios; Nikhil Revankar; Peng Xu; Gwilym Thompson; Joel Bobula; Loretto Lacey; Maren Gaudig
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

2.  Societal and Family Lifetime Cost of Dementia: Implications for Policy.

Authors:  Eric Jutkowitz; Robert L Kane; Joseph E Gaugler; Richard F MacLehose; Bryan Dowd; Karen M Kuntz
Journal:  J Am Geriatr Soc       Date:  2017-08-17       Impact factor: 5.562

3.  Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease.

Authors:  Tzeyu L Michaud; Robin High; Mary E Charlton; Daniel L Murman
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jul-Sep       Impact factor: 2.703

Review 4.  Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Authors:  James Shearer; Colin Green; Craig W Ritchie; John P Zajicek
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

Review 5.  Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.

Authors:  Luis Hernandez; Asli Ozen; Rodrigo DosSantos; Denis Getsios
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

6.  Gene Expressions, Hippocampal Volume Loss, and MMSE Scores in Computation of Progression and Pharmacologic Therapy Effects for Alzheimer's Disease.

Authors:  Aydin Saribudak; Adarsha A Subick; Na Hyun Kim; Joshua A Rutta; M Umit Uyar
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2018-09-14       Impact factor: 3.710

7.  A new algorithm for predicting time to disease endpoints in Alzheimer's disease patients.

Authors:  Qolamreza R Razlighi; Eric Stallard; Jason Brandt; Deborah Blacker; Marilyn Albert; Nikolaos Scarmeas; Bruce Kinosian; Anatoliy I Yashin; Yaakov Stern
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 8.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis.

Authors:  S L Bermingham
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

9.  Validation and demonstration of a new comprehensive model of Alzheimer's disease progression.

Authors:  Yaakov Stern; Eric Stallard; Bruce Kinosian; Carolyn Zhu; Stephanie Cosentino; Zhezhen Jin; Yian Gu
Journal:  Alzheimers Dement       Date:  2021-05-14       Impact factor: 21.566

10.  The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study.

Authors:  Ilona Hallikainen; Janne Martikainen; Pei-Jung Lin; Joshua T Cohen; Raquel Lahoz; Tarja Välimäki; Kristiina Hongisto; Saku Väätäinen; Matti Vanhanen; Peter J Neumann; Tuomo Hänninen; Anne Maria Koivisto
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.